Efficacy of CAR T-Cell Therapy is Not Impaired by Previous Bispecific Antibody Treatment in Large B-Cell Lymphoma.
Abstract
In this retrospective study, CAR T-cells remained effective in relapsed/refractory LBCL patients after prior exposure to bispecific antibodies (BsAbs) targeting different antigens. These results are relevant to clinical practice, particularly given the increasing use of BsAbs in earlier treatment lines.
Domains
Cancer
Fichier principal
Crochet et al. - 2024 - Efficacy of CAR T-Cell Therapy is Not Impaired by .pdf (484.92 Ko)
Télécharger le fichier
| Origin | Files produced by the author(s) |
|---|
